Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus
- 1 June 2010
- journal article
- research article
- Published by Elsevier in The American Journal of Surgery
- Vol. 199 (6) , 804-816
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Skin and Soft‐Tissue Infections Caused by Community‐Acquired Methicillin‐ResistantStaphylococcus aureusClinical Infectious Diseases, 2008
- What Is Community‐Associated Methicillin‐ResistantStaphylococcus aureus?The Journal of Infectious Diseases, 2008
- The importance of the development of antibiotic resistance in Staphylococcus aureusClinical Microbiology and Infection, 2006
- Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA)International Journal of Antimicrobial Agents, 2005
- Linezolid versus Vancomycin in Treatment of Complicated Skin and Soft Tissue InfectionsAntimicrobial Agents and Chemotherapy, 2005
- Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureusThe American Journal of Surgery, 2005
- Linezolid eradicates MRSA better than vancomycin from surgical-site infectionsThe American Journal of Surgery, 2004
- Treating Foot Infections in Diabetic Patients: A Randomized, Multicenter, Open‐Label Trial of Linezolid versus Ampicillin‐Sulbactam/Amoxicillin‐ClavulanateClinical Infectious Diseases, 2004
- Linezolid versus Vancomycin for the Treatment of Methicillin‐ResistantStaphylococcus aureusInfectionsClinical Infectious Diseases, 2002
- Pharmacokinetics and Tissue Penetration of Linezolid following Multiple Oral DosesAntimicrobial Agents and Chemotherapy, 2001